Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BMEA | US
-0.12
-9.45%
Healthcare
Biotechnology
30/06/2024
08/06/2026
1.15
1.22
1.23
1.10
Biomea Fusion Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219 an orally bioavailable potent and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion Inc. was incorporated in 2017 and is headquartered in Redwood City California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Short percentage (> 15%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
70.1%1 month
75.6%3 months
103.8%6 months
92.4%-
-
3.98
0.10
0.08
-3.75
-
-
-146.72M
41.64M
41.64M
-
-
-
-
-85.09
9.35
35.67
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.38
Range1M
0.59
Range3M
1.17
Rel. volume
1.93
Price X volume
2.63M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.99 | 45.31M | -2.94% | n/a | 28.90% |
| BioXcel Therapeutics Inc | BTAI | Biotechnology | 1.105 | 45.02M | 0.00% | n/a | -139.46% |
| PEPG | PEPG | Biotechnology | 1.35 | 44.00M | -4.26% | n/a | 12.52% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.41 | 43.67M | -1.40% | n/a | 1.95% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.2 | 43.59M | 1.69% | n/a | 3.91% |
| QNCX | QNCX | Biotechnology | 1 | 43.28M | -0.99% | n/a | 30.62% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.69 | 43.15M | -0.59% | n/a | 6.85% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.33 | 42.44M | -2.20% | n/a | -6472.02% |
| Akanda Corp. Common Shares | AKAN | Drug Manufacturers-Specialty & Generic | 14.65 | 41.81M | -6.27% | n/a | -104.44% |
| Lantern Pharma Inc. | LTRN | Biotechnology | 3.75 | 40.37M | 4.46% | n/a | 0.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.08 | 32.10M | -0.02% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.75 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.98 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 103.80 | 72.80 | Riskier |
| Debt to Equity | 0.10 | -1.23 | Expensive |
| Debt to Assets | 0.08 | 0.25 | Cheaper |
| Market Cap | 41.64M | 3.66B | Emerging |